Smoking Cessation Treatment for Patients With Mental Disorders Using CBT and Combined Pharmacotherapy

Loreto, Aline Rodrigues; Carvalho, Carlos Felipe Cavalcanti; Frallonardo, Fernanda Piotto; Ismael, Flávia; Andrade, Arthur Guerra de; Castaldelli-Maia, João Maurício

doi:10.1080/15504263.2017.1328149

Cited by 30 publications

(28 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, studies suggest that patients with schizophrenia are at least as motivated to quit as the general population but have lesser chance to quit attempts (17, 18). Moreover, several studies suggest that tobacco dependence treatment is effective in patients with mental illness (9, 19, 20), with some exploring the safety and efficacy of pharmacological treatment in this group (21, 22). Despite that, most psychiatric services do not address smoking cessation in patients with schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

Stop Turning a Blind Eye: Tobacco Smoking Among Egyptian Patients With Schizophrenia

et al. 2019

View full text Add to dashboard Cite

Background: Patients with schizophrenia have considerably higher rates of mortality than general population. Multiple factors may play a role in this. Despite being a major preventable cause of death, smoking is usually overlooked when dealing with patients with schizophrenia. Understanding the pattern of smoking, its severity, and the reasons to quit might be helpful in managing patients with schizophrenia and decreasing the mortality gap.Subjects and Methods: The study included smokers divided into two groups; the first included 346 patients with schizophrenia while the second group had 150 smokers with no mental illness. Both groups were assessed and compared regarding sociodemographic variables, pattern of smoking, severity of nicotine dependence, and motivation to quit smoking.Results: Earlier age of starting to smoke, higher number of cigarettes per day, and lower dependency scores were noted in patients with Schizophrenia. Positive correlation was found between positive symptoms and severity of dependence. Specific positive symptoms were correlated to number of cigarettes per day and time before first cigarette. Patients with Schizophrenia showed a significant difference in intrinsic reasons to quit (health concerns and self-control), which were also positively correlated to their positive symptoms score. Linear regression analysis for predictors of FTND score revealed that only age, sex, and schizophrenia were significant predictors of FTND score.Conclusion: Patients with schizophrenia smoke at earlier ages and smoke more cigarettes per day, yet, have less severe dependence than non-schizophrenic counterparts. Positive symptoms play a role in their smoking pattern and severity. Health concerns and self-control are their main motives to quit smoking.

show abstract

Section: Introductionmentioning

confidence: 99%

Stop Turning a Blind Eye: Tobacco Smoking Among Egyptian Patients With Schizophrenia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Importantly, non-biomedical interventions—such as cognitive behavioral therapy and motivational interviewing—are indeed effective treatments for addiction (Hettema, Steele, & Miller, 2005; McHugh, Hearon, & Otto, 2010), including when offered in combination with pharmacotherapy (Loreto et al, 2017). However, patients are most likely to benefit from an addiction treatment if they believe that treatment is likely to be effective and feel confident in their own agency and self-efficacy (i.e., perceive themselves as capable of succeeding in their efforts to overcome their addictions) (Cropsey et al, 2014; DiClemente, Doyle, & Donovan, 2009; Kadden & Litt, 2011; Laudet & Stanick, 2010; Moos, 2007).…”

Section: Introductionmentioning

confidence: 99%

Beneficial and detrimental effects of genetic explanations for addiction

Lebowitz

Appelbaum

2017

Int J Soc Psychiatry

View full text Add to dashboard Cite

Background Addictions are highly stigmatized and increasingly construed as biomedical diseases caused by genes, partly to reduce stigma by deflecting blame. However, genetic explanations may have negative effects, which have been understudied in the context of addiction. How the effects of genetic explanations might differ for substance addiction versus behavioral addictions is also unknown. Aims This study examined the impact of genetic explanations for addiction on measures of treatment expectancies, blame, and perceived agency and self-control, as well as whether these varied depending whether the addiction was to a substance or a behavior. Methods Participants read about a person (“Charlie”) with either alcohol use disorder or gambling disorder, receiving either a genetic or nongenetic explanation of Charlie’s problem. They rated how much they blamed Charlie for his disorder, his likelihood of benefitting from medication or psychotherapy, and how much agency and self-control they ascribed to him. Results Compared to the nongenetic explanation, the genetic explanation reduced blame and increased confidence in the effectiveness of pharmacotherapy. However, it also decreased the expected effectiveness of psychotherapy and reduced ascriptions of agency and self-control. Conclusions Genetic explanations for addiction appear to be a “double-edged sword,” with beneficial effects that come at a cost.

show abstract

“…Exclusion criteria included living outside the city of São Caetano do Sul; being younger than 18 or older than 65; did not legibly complete the initial questionnaire; being pregnant. Last, smokers with a history of substance use disorder had to be abstinent for a minimum period of one year to be included in the present study – this unit has adopted this requirement based on data suggesting that delayed treatment for tobacco use yields the best outcomes for substance use disorders and tobacco dependence [3, 15, 21].…”

Section: Methodsmentioning

confidence: 99%

Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study

et al. 2018

Self Cite

View full text Add to dashboard Cite

The inclusion of individuals with and without MSUD in the same protocol, allowing for individuals with MSUD undergoing their psychiatric treatment, generates at least comparable success rates between the groups. Predictors of treatment success were similar to those found in the general population. Facilities that treat patients with MSUD should treat tobacco use in order to reduce the disparities in morbidity and mortality experienced by this population.

show abstract

Smoking Cessation Treatment for Patients With Mental Disorders Using CBT and Combined Pharmacotherapy

Cited by 30 publications

References 41 publications

Stop Turning a Blind Eye: Tobacco Smoking Among Egyptian Patients With Schizophrenia

Stop Turning a Blind Eye: Tobacco Smoking Among Egyptian Patients With Schizophrenia

Beneficial and detrimental effects of genetic explanations for addiction

Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study

Contact Info

Product

Resources

About